|
Both apoptosis induction and viability loss, measured in response to treatment with either topotecan, a topoisomerase I inhibitor derived from camptothecin Figure 4C, or doxorubicin, an anthracycline intercalator that inhibits the progression of the topoisomerase II and stabilizes its complex with cleaved DNA Figure 4D, are considerably more marked in HCT 116 cells as compared to either of the mutant KRAS deleted derivative lines, HKE 3 and HKH 2 buy cialis daily online Further research is needed to identify the most suitable types of SERMs to treat OA and to clearly identify their action mechanisms on joint tissues |
|